Table 2.
Clinical Outcomes.
| Outcome | Early EN (n=31) | Delayed EN (n=67) | p Value |
|---|---|---|---|
| Mortality | 0 | 8 (11.9%) | 0.045 |
| Length of hospital stay, days | 18 (12-30) | 27 (18-43) | 0.001 |
| Intensive care admission | 1 (3.2%) | 14 (20.9%) | 0.032 |
| Surgical intervention | 0 | 5 (7.5%) | 0.18 |
| Improvements of blood tests results After 7-10 days of EN | |||
| Total bilirubin, μmol/L | 2.9 (-0.5-10.8) | 11.7 (5.8-25.1) | 0.31 |
| Total protein, g/L | -3.9 (-9.2-1.3) | 2.1 (-5.4-6.1) | 0.03 |
| White blood cell, 103/μL | 4.0 (0.8-6.6) | 4.4 (0.1-7.5) | 0.72 |
| CRP, mg/L | 129.0 (63.8-177.4) | 31.7 (-6.1-123.8) | 0.006 |
| Pancreatic necrosis | 27 (87.0%) | 61 (91.0%) | 0.72 |
| Infected pancreatic necrosis | 1 (3.2%) | 11 (16.4%) | 0.096 |
| Bacteremia | 0 | 7 (10.4%) | 0.094 |
| Polymicrobial infection | 5 (16.1%) | 20 (29.8%) | 0.15 |
| MDRO | 5 (16.1%) | 14 (20.9%) | 0.78 |
| Hospital care costs, US$ | 9289 (6263-12844) | 13518 (10106-20392) | 0.007 |
Data expressed as n (%), or median (IQR).
The bold values indicate that there was a significant difference.
CRP, C-reactive protein; EN, enteral nutrition; MDRO, multiple drug resistant organism.